Other safety alerts
|
| |
| The United States: FDA Drug Safety Communication: FDA warns about rare but serious allergic reactions with the skin antiseptic chlorhexidine gluconate |
| |
The U.S. Food and Drug Administration (FDA) is warning that rare but serious allergic reactions have been reported with the widely used skin antiseptic products containing chlorhexidine gluconate. Although rare, the number of reports of serious allergic reactions to these products has increased over the last several years. As a result, FDA is requesting the manufacturers of over-the-counter (OTC) antiseptic products containing chlorhexidine gluconate to add a warning about this risk to the Drug Facts labels. Prescription chlorhexidine gluconate mouthwashes and oral chips used for gum disease already contain a warning about the possibility of serious allergic reactions in their labels.
In the US, chlorhexidine gluconate is mainly available in OTC products to clean and prepare the skin before surgery and before injections in order to help reduce bacteria that potentially can cause skin infections. These products are available as solutions, washes, sponges, and swabs and under many different brand names and as generics. Chlorhexidine gluconate is also available as a prescription mouthwash to treat gingivitis and as a prescription oral chip to treat periodontal disease. In 1998, FDA issued a Public Health Notice to warn health care professionals about the risk of serious allergic reactions with medical devices such as dressings and intravenous lines that contain chlorhexidine gluconate.
FDA identified 52 cases of anaphylaxis, a severe form of allergic reaction, with the use of chlorhexidine gluconate products applied to the skin. In the 46 years between January 1969 and early June 2015, FDA received reports of 43 cases worldwide. More than half of the 43 cases were reported after 2010, and after the FDA 1998 Public Health Notice. This number includes only reports submitted to FDA, so there are likely additional cases about which FDA is unaware. The serious allergic reaction cases reported outcomes that required emergency department visits or hospitalizations to receive drug and other medical treatments. These allergic reactions resulted in two deaths. Eight additional cases of anaphylaxis were published in the medical literature between 1971 and 2015, and one case was identified in the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance (NEISS-CADES) database between 2004 and 2013.
Patients and consumers should stop using the product that contains chlorhexidine gluconate and seek medical attention immediately if they experience symptoms of a serious allergic reaction. These reactions can occur within minutes of exposure. Symptoms include wheezing or difficulty breathing; swelling of the face; hives that can quickly progress to more serious symptoms; severe rash; or shock, which is a life-threatening condition that occurs when the body is not getting enough blood flow.
Health care professionals should always ask patients if they have ever had an allergic reaction to any antiseptic before recommending or prescribing a chlorhexidine gluconate product. Advise patients to seek immediate medical attention if they experience any symptoms of an allergic reaction when using the products. Consider using alternative antiseptics such as povidone-iodine, alcohols, benzalkonium chloride, benzethonium chloride, or parachlorometaxylenol (PCMX) when any previous allergy to chlorhexidine gluconate is documented or suspected.
Please refer to the following website in FDA for details:
http://www.fda.gov/Drugs/DrugSafety/ucm530975.htm
In Hong Kong, there are 81 registered pharmaceutical products containing chlorhexidine, of which 58 products are over-the-counter medicines. News related to anaphylactic reaction for medicinal products containing chlorhexidine was previously issued by the MHRA, and was posted on the Drug Office website on 26 October 2012. Letters to inform local healthcare professionals were also issued on the same day. So far, the Department of Health has received two cases of adverse drug reaction in connection with chlorhexidine mouthwash and spray, and the cases were not related to allergic reactions. In view of the above US FDA announcement, the matter will be discussed by the Registration Committee of the Pharmacy and Poisons Board.
Ends/ Friday, February 03, 2017
Issued at HKT 15:00
|
| |
|
